article thumbnail

CBD, THC & CBG for Skin Conditions

Project CBD

Anyone who has paid any attention to the cannabis “wellness” industry in recent years — whether through state medical and recreational programs or the free-for-all national CBD market — will be familiar with cannabinoid-infused topicals marketed to treat minor aches and pains.

article thumbnail

Answer of the Day for Aug 29, 2022

TheAnswerPage

“The Answer of the Day” series on the treatment effects of cannabinoids continues… According to randomized controlled trials, which health conditions does nabiximols (Sativex – ~50:50 THC:CBD plant-derived product) effectively treat? BMC Med 20, 259 (2022). Spanagel, R. See the Answer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Answer of the Day for Mar 5, 2022

TheAnswerPage

What are the 5 most common physical health reasons medical marijuana patients use cannabinoid-based therapeutics? What are the 5 most common mental health reasons medical marijuana patients use cannabinoid-based therapeutics? Psychopharmacology (2022). Stjepanovi?, See the Answer.

Sleep 52
article thumbnail

Oregon’s New Artificially Derived Cannabinoid Rules Begin July 1

Cannabis Law Report

Artificially derived cannabinoid (ADC) products are leaving Oregon grocery stores and convenience stores beginning July 1, 2022. CBN is currently the most popular ADC and many consumers take the product as a sleeping aid. Indeed, the OLCC RAC package was titled “Delta-8-THC and Other Artificially-Derived Cannabinoids”.

article thumbnail

OLCC Finalizes New Rules on Delta-8 THC and other Artificially Derived Cannabinoids

Cannabis Law Report

The Oregon Liquor Control Commission (OLCC) recently finalized new administrative rules on Delta-8 THC and other artificially derived cannabinoids as directed by HB 3000 (2021). Delta-8 THC and other Artificially Derived Cannabinoids. Artificially Derived Cannabinoids Allowed in SOME Situations.

article thumbnail

Canopy Growth to Report Q2 2022 Financial Results on November 5, 2021

Cannabis Law Report

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED,NASDAQ: CGC ) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 , before financial markets open on November 5, 2021. A replay will be accessible by webcast until 11:59 PM ET on February 3, 2022 at: [link].

Sleep 52
article thumbnail

Answer of the Day for Jul 23, 2022

TheAnswerPage

The “Cannabinoid-based Medications for the Treatment of Chronic Pain” series continues… As described in the previous Answer of the Day, the September 9, 2021 edition of the British Medical Journal contained the guidelines entitled “Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.”